Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CBAY - Cymabay Therapeutics Inc

IEX Last Trade
12.4
0.260   2.097%

Share volume: 1,338,346
Last Updated: Tue 08 Aug 2023 09:59:57 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%
$12.14
0.26
2.14%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 3%
Liquidity 45%
Performance 37%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$12.40
P/E Ratio 
0.00
DAY RANGE
$11.92 - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
114.724 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Sujal Shah
Region: US
Website: http://www.cymabay.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

Recent news